128 related articles for article (PubMed ID: 8385988)
1. Soluble tumor necrosis factor receptor expression in patients with metastatic renal cell carcinoma treated with interleukin-2-based immunotherapy.
Belldegrun A; Pierce W; Sayah D; deKernion J; Wallach D; Aderka D; Figlin RA
J Immunother Emphasis Tumor Immunol; 1993 Apr; 13(3):175-80. PubMed ID: 8385988
[TBL] [Abstract][Full Text] [Related]
2. Interferon-alpha primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinoma.
Belldegrun A; Pierce W; Kaboo R; Tso CL; Shau H; Turcillo P; Moldawer N; Golub S; deKernion J; Figlin R
J Urol; 1993 Nov; 150(5 Pt 1):1384-90. PubMed ID: 8411405
[TBL] [Abstract][Full Text] [Related]
3. Relationship between soluble tumor necrosis factor (TNF) receptors and TNF alpha during immunotherapy with interleukin-2 and/or interferon alpha.
Landmann R; Keilholz U; Scheibenbogen C; Brockhaus M; Gallati H; Denz H; Bargetzi M; Ludwig C
Cancer Immunol Immunother; 1994 Feb; 38(2):113-8. PubMed ID: 8306366
[TBL] [Abstract][Full Text] [Related]
4. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
[TBL] [Abstract][Full Text] [Related]
5. [Has interleukin 2 modified the outcome of metastatic kidney cancer?].
Négrier S; Philip T
Ann Urol (Paris); 1993; 27(2):87-9. PubMed ID: 8503657
[TBL] [Abstract][Full Text] [Related]
6. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor.
Figlin RA; Pierce WC; Kaboo R; Tso CL; Moldawer N; Gitlitz B; deKernion J; Belldegrun A
J Urol; 1997 Sep; 158(3 Pt 1):740-5. PubMed ID: 9258071
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of cytokines and soluble cytokine receptors in patients with metastatic renal cell carcinoma or malignant melanoma receiving IL-2/interferon-alpha combination therapy.
Fosså SD; Aamdal S; Naume B; Gallati H
Acta Oncol; 1995; 34(5):599-603. PubMed ID: 7546824
[TBL] [Abstract][Full Text] [Related]
8. Induction of soluble tumour necrosis factor receptors during treatment with interleukin-2.
Miles DW; Aderka D; Engelmann H; Wallach D; Balkwill FR
Br J Cancer; 1992 Dec; 66(6):1195-9. PubMed ID: 1333789
[TBL] [Abstract][Full Text] [Related]
9. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
10. Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes.
Hänninen EL; Körfer A; Hadam M; Schneekloth C; Dallmann I; Menzel T; Kirchner H; Poliwoda H; Atzpodien J
Cancer Res; 1991 Dec; 51(23 Pt 1):6312-6. PubMed ID: 1933892
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.
Figlin R; Gitlitz B; Franklin J; Dorey F; Moldawer N; Rausch J; deKernion J; Belldegrun A
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S92-7. PubMed ID: 9457402
[TBL] [Abstract][Full Text] [Related]
12. Patterns of cytokine release of unselected and CD8+ selected renal cell carcinoma tumor-infiltrating lymphocytes (TIL). Evidence for enhanced specific killing of tumor necrosis factor-secreting/IL-6 nonsecreting TIL in vitro and correlation with complete response in vivo.
Steger GG; Pierce WC; Figlin R; Czernin J; Kaboo R; DeKernion JB; Okarma T; Belldegrun A
Clin Immunol Immunopathol; 1994 Aug; 72(2):237-47. PubMed ID: 8050198
[TBL] [Abstract][Full Text] [Related]
13. Cancer immunotherapy using tumor-infiltrating lymphocytes.
Figlin RA
Semin Hematol; 1992 Apr; 29(2 Suppl 1):33-5. PubMed ID: 1535456
[No Abstract] [Full Text] [Related]
14. Studies of the immunological effects of interleukin-2 in patients with bladder cancer and renal cell carcinoma.
Hermann GG
APMIS Suppl; 1993; 35():1-26. PubMed ID: 8251200
[No Abstract] [Full Text] [Related]
15. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
[TBL] [Abstract][Full Text] [Related]
16. Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma.
Figlin RA; Pierce WC; Belldegrun A
Semin Oncol; 1993 Dec; 20(6 Suppl 9):11-5. PubMed ID: 8284686
[No Abstract] [Full Text] [Related]
17. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy.
Cangiano T; Liao J; Naitoh J; Dorey F; Figlin R; Belldegrun A
J Clin Oncol; 1999 Feb; 17(2):523-8. PubMed ID: 10080595
[TBL] [Abstract][Full Text] [Related]
18. [Chances for the success of cytokine therapy in metastatic renal cell cancer].
Kriegmair M
Fortschr Med; 1992 Aug; 110(24):435-6. PubMed ID: 1398389
[No Abstract] [Full Text] [Related]
19. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
20. Peripheral blood neutrophils as independent immunologic predictor of response and long-term survival upon immunotherapy in metastatic renal-cell carcinoma.
Atzpodien J; Reitz M
Cancer Biother Radiopharm; 2008 Feb; 23(1):129-34. PubMed ID: 18298337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]